Date: 2011-02-07
Type of information: Licensing agreement
Compound: RNAi-based therapy
Company: Debiopharm (Switzerland) Marina Biotech (USA)
Therapeutic area: Cancer Oncology
Type agreement: licensing
development
commercialisation
Action mechanism:
Disease: bladder cancer
Details: The Debiopharm Group and Marina Biotech, RNAi-based drug discovery and development company, have entered into an exclusive agreement concerning the development and commercialisation of Marina Biotech’s pre-clinical programme in bladder cancer. Debiopharm and Marina Biotech will work together to advance to market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will have full responsibility for the development and commercialisation of any products arising from the partnership.
Financial terms: Under the terms of the agreement, Debiopharm will pay Marina Biotech up to $25 million based on predefined research and development milestones as well as royalties on the sales of products resulting from the partnership. In addition, all Marina Biotech research and development costs for the bladder cancer programme will be funded by Debiopharm beginning in February 2011. Further terms of the agreement were not disclosed.
Latest news: